vs
Side-by-side financial comparison of PILGRIMS PRIDE CORP (PPC) and Regeneron Pharmaceuticals (REGN). Click either name above to swap in a different company.
PILGRIMS PRIDE CORP is the larger business by last-quarter revenue ($4.5B vs $3.6B, roughly 1.3× Regeneron Pharmaceuticals). Regeneron Pharmaceuticals runs the higher net margin — 20.2% vs 2.2%, a 17.9% gap on every dollar of revenue. On growth, Regeneron Pharmaceuticals posted the faster year-over-year revenue change (19.0% vs 1.6%). Over the past eight quarters, Regeneron Pharmaceuticals's revenue compounded faster (0.8% CAGR vs -0.3%).
Pilgrim's Pride Corporation is an American, multi-national food company, currently one of the largest chicken producers in the United States and Puerto Rico and the second-largest chicken producer in Mexico. It exited bankruptcy in December 2009 and relocated its U.S. headquarters to Greeley, Colorado, in 2011. It is majority-owned by JBS S.A. Pilgrim's Pride purchased Gold'n Plump for $350 million in late November 2016.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
PPC vs REGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.5B | $3.6B |
| Net Profit | $101.5M | $727.0M |
| Gross Margin | 7.6% | 89.6% |
| Operating Margin | 3.6% | 17.8% |
| Net Margin | 2.2% | 20.2% |
| Revenue YoY | 1.6% | 19.0% |
| Net Profit YoY | — | -10.1% |
| EPS (diluted) | $0.43 | $6.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.5B | $3.6B | ||
| Q4 25 | $4.5B | $3.9B | ||
| Q3 25 | $4.8B | $3.8B | ||
| Q2 25 | $4.8B | $3.7B | ||
| Q1 25 | $4.5B | $3.0B | ||
| Q4 24 | $4.4B | $3.8B | ||
| Q3 24 | $4.6B | $3.7B | ||
| Q2 24 | $4.6B | $3.5B |
| Q1 26 | $101.5M | $727.0M | ||
| Q4 25 | $88.0M | $844.6M | ||
| Q3 25 | $342.8M | $1.5B | ||
| Q2 25 | $355.5M | $1.4B | ||
| Q1 25 | $296.0M | $808.7M | ||
| Q4 24 | $235.9M | $917.7M | ||
| Q3 24 | $349.9M | $1.3B | ||
| Q2 24 | $326.3M | $1.4B |
| Q1 26 | 7.6% | 89.6% | ||
| Q4 25 | 9.5% | — | ||
| Q3 25 | 13.9% | — | ||
| Q2 25 | 15.0% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 14.9% | — | ||
| Q2 24 | 15.2% | — |
| Q1 26 | 3.6% | 17.8% | ||
| Q4 25 | 4.5% | 22.7% | ||
| Q3 25 | 10.4% | 27.3% | ||
| Q2 25 | 10.8% | 29.4% | ||
| Q1 25 | 9.1% | 19.5% | ||
| Q4 24 | 7.0% | 26.1% | ||
| Q3 24 | 11.1% | 31.7% | ||
| Q2 24 | 9.7% | 30.2% |
| Q1 26 | 2.2% | 20.2% | ||
| Q4 25 | 1.9% | 21.7% | ||
| Q3 25 | 7.2% | 38.9% | ||
| Q2 25 | 7.5% | 37.9% | ||
| Q1 25 | 6.6% | 26.7% | ||
| Q4 24 | 5.4% | 24.2% | ||
| Q3 24 | 7.6% | 36.0% | ||
| Q2 24 | 7.2% | 40.4% |
| Q1 26 | $0.43 | $6.75 | ||
| Q4 25 | $0.37 | $7.78 | ||
| Q3 25 | $1.44 | $13.62 | ||
| Q2 25 | $1.49 | $12.81 | ||
| Q1 25 | $1.24 | $7.27 | ||
| Q4 24 | $1.00 | $8.12 | ||
| Q3 24 | $1.47 | $11.54 | ||
| Q2 24 | $1.37 | $12.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $542.4M | — |
| Total DebtLower is stronger | $3.1B | $2.0B |
| Stockholders' EquityBook value | $3.7B | $31.4B |
| Total Assets | $10.2B | $40.9B |
| Debt / EquityLower = less leverage | 0.83× | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $542.4M | — | ||
| Q4 25 | $640.2M | $8.6B | ||
| Q3 25 | $612.6M | $8.4B | ||
| Q2 25 | $849.0M | $7.5B | ||
| Q1 25 | $2.1B | $8.3B | ||
| Q4 24 | $2.0B | $9.0B | ||
| Q3 24 | $1.9B | $9.8B | ||
| Q2 24 | $1.3B | $9.8B |
| Q1 26 | $3.1B | $2.0B | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $3.1B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.2B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — |
| Q1 26 | $3.7B | $31.4B | ||
| Q4 25 | $3.7B | $31.3B | ||
| Q3 25 | $3.5B | $31.0B | ||
| Q2 25 | $3.7B | $29.9B | ||
| Q1 25 | $3.1B | $29.4B | ||
| Q4 24 | $4.2B | $29.4B | ||
| Q3 24 | $4.2B | $29.3B | ||
| Q2 24 | $3.7B | $28.2B |
| Q1 26 | $10.2B | $40.9B | ||
| Q4 25 | $10.3B | $40.6B | ||
| Q3 25 | $10.0B | $40.2B | ||
| Q2 25 | $10.1B | $38.2B | ||
| Q1 25 | $11.0B | $37.5B | ||
| Q4 24 | $10.7B | $37.8B | ||
| Q3 24 | $10.7B | $37.4B | ||
| Q2 24 | $10.1B | $36.1B |
| Q1 26 | 0.83× | 0.06× | ||
| Q4 25 | 0.84× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $1.1B |
| Free Cash FlowOCF − Capex | — | $848.3M |
| FCF MarginFCF / Revenue | — | 23.5% |
| Capex IntensityCapex / Revenue | — | 6.4% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.1B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $291.2M | $1.2B | ||
| Q3 25 | $458.3M | $1.6B | ||
| Q2 25 | $495.2M | $1.1B | ||
| Q1 25 | $126.9M | $1.0B | ||
| Q4 24 | $349.3M | $1.3B | ||
| Q3 24 | $651.1M | $1.3B | ||
| Q2 24 | $718.6M | $354.0M |
| Q1 26 | — | $848.3M | ||
| Q4 25 | $10.0M | $922.0M | ||
| Q3 25 | $275.9M | $1.4B | ||
| Q2 25 | $339.1M | $925.4M | ||
| Q1 25 | $28.1M | $815.8M | ||
| Q4 24 | $176.6M | $1.1B | ||
| Q3 24 | $565.3M | $1.0B | ||
| Q2 24 | $617.7M | $173.5M |
| Q1 26 | — | 23.5% | ||
| Q4 25 | 0.2% | 23.7% | ||
| Q3 25 | 5.8% | 37.8% | ||
| Q2 25 | 7.1% | 25.2% | ||
| Q1 25 | 0.6% | 26.9% | ||
| Q4 24 | 4.0% | 28.1% | ||
| Q3 24 | 12.3% | 28.2% | ||
| Q2 24 | 13.5% | 4.9% |
| Q1 26 | — | 6.4% | ||
| Q4 25 | 6.2% | 6.4% | ||
| Q3 25 | 3.8% | 5.4% | ||
| Q2 25 | 3.3% | 6.0% | ||
| Q1 25 | 2.2% | 7.6% | ||
| Q4 24 | 4.0% | 5.3% | ||
| Q3 24 | 1.9% | 6.5% | ||
| Q2 24 | 2.2% | 5.1% |
| Q1 26 | — | 1.48× | ||
| Q4 25 | 3.31× | 1.39× | ||
| Q3 25 | 1.34× | 1.11× | ||
| Q2 25 | 1.39× | 0.82× | ||
| Q1 25 | 0.43× | 1.29× | ||
| Q4 24 | 1.48× | 1.38× | ||
| Q3 24 | 1.86× | 0.96× | ||
| Q2 24 | 2.20× | 0.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PPC
| U.S | $2.6B | 58% |
| Europe | $1.4B | 30% |
| Mexico | $545.5M | 12% |
REGN
| Sanofi | $1.6B | 45% |
| Other | $507.0M | 14% |
| EYLEA - U.S | $473.0M | 13% |
| Bayer | $287.0M | 8% |
| Libtayo ® - U.S | $286.0M | 8% |
| Other revenue | $171.0M | 5% |
| Libtayo - ROW* | $152.0M | 4% |
| Praluent - U.S | $67.0M | 2% |
| Evkeeza ® - U.S | $46.0M | 1% |
| Lynozyfic ® - Global | $11.0M | 0% |
